F, the benefits of neoadjuvant DPP-4 chemotherapy is that it allows an accurate assessment of therapeutic response. The term pathologic response that means completely Requests reference requests getting disappearance of tumor cells in the sample w Received during the final surgery after neoadjuvant chemotherapy. Although instances of PCR are relatively rare, and for most sharing plans, the PCR is performed in only 10 to 20% of patients, the PCR is the most important prognostic parameters in women with neoadjuvant chemotherapy. In this study, we conducted a retrospective single institution results of neoadjuvant therapy in breast cancer patients treated with three different patterns. Patients and Methods This study is a retrospective analysis of the results of neoadjuvant chemotherapy in consecutive patients, 376 375 women and 1 man, aged 54 10, range 22 78 years, diagnosed with breast cancer was histologically best CONFIRMS that began in treatment between January 1998 and December 2008 at the Department of Oncology and Radiotherapy, University tsklinikum the Charles University t Hradec Kra love, Czech Republic.
This project was approved by the Ethics Commission. Bilateral mammography and staging, which were R Ntgenuntersuchung included chest, abdominal ultrasound, and scintigraphy within 2 months after initiation of treatment carried out. In the case of dilute emissions Mighty L CT was performed. Patients were treated with three different treatments of neoadjuvant chemotherapy, a standard protocol on the gel Treated walls. Between 1998 and 2003, patients were treated with 3 to 6 cycles of paclitaxel and doxorubicin combination every 3 weeks. As of 2003 patients were treated with doxorubicin and cyclophosphamide dose dense sequential combination with w Weekly paclitaxel treatment. The Di was t of four doses of doxorubicin and cyclophosphamide administered every 14 days by 12 doses of paclitaxel in w Chentlichen distances Ends are given, followed. Granulocyte-colony stimulating factor was administered after each dose of doxorubicin and cyclophosphamide, and, for neutropenia, also may need during the w Chentlichen administration of paclitaxel.
From 2006, patients were expressing with human epidermal growth factor-2 in breast cancer with four doses of doxorubicin and DD regimes treated as described above cyclophosphamide announced either, or by the combination followed by 12 doses w Weekly trastuzumab, paclitaxel, and in most patients, carboplatin. After surgery, patients were treated with radiotherapy and adjuvant hormonal therapy after the Locational guidelines discussed. The punch biopsy for both the diagnosis and the resected specimen obtained at surgery after neoadjuvant chemotherapy evaluated. The tissue was fixed in 10% formalin, routinely Strength processed and embedded in paraffin. Four sections were stained with H Matoxylin and eosin In May Grünwald Giemsa and Gru Rbt. All Objekttr hunter, with the exception of surgical specimens from two patients in the Au Enseite operate our center were reviewed by a pathologist. Zus Tzlich for routinely for take-F Staining were detected in all F Cases examined by immunohistochemistry. For immunohistochemistry 2 lm sections were prepared, and an indirect immunohistochemical wa.